New Delhi, October 23, 2016: Celon Pharma S.A.’s IPO was held on the main market of the Warsaw Stock Exchange on 17 October 2016. The share price on the first day of trading increased by 17.58 percent. 15,000,000 of B series ordinary shares were introduced into the regulated market of the Warsaw Stock Exchange on the basis of a prospectus approved by the Polish Financial Supervision Authority (KNF).
Mercurius Dom Maklerski Sp. z o.o. was the Offerer in the process.
Maciej Wieczorek, CEO of Celon Pharma S.A.: Today I wish to thank the investors for the trust they gave to our Company and ensure them that I will be fully committed not to let them down.
Celon Pharma S.A. is a pharmaceutical company with an established position, growing revenues and a very clear vision of the future which implies both a dynamic international expansion of our flagship product and our constant presence in the race to conquer global pharmaceutical markets. This is also a vision which will help us effectively develop several innovative projects and commercialise them effectively in the next few years – adds Maciej Wieczorek.
Celon Pharma S.A. is the first biopharmaceutical company which at the same time specialises in developing, manufacturing and marketing of specialised generic drugs, as well as conducting research on innovative therapies to be listed on the Warsaw Stock Exchange. The Company’s current product portfolio can be divided into standard generic drugs, combination generic drugs, and designs of new drugs, including potential innovative drugs. Celon Pharma S.A. has two fully equipped laboratories dedicated to research and development of medicinal products (R&D) for both generic and innovative drugs. It also has a modern manufacturing facility in Kazuń Nowy where dry pharmaceutical forms are manufactured.
Corporate Comm India(CCI Newswire)
